168 related articles for article (PubMed ID: 36991231)
1. Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study.
Dufour J; Choquet S; Hoang-Xuan K; Schmitt A; Ahle G; Houot R; Taillandier L; Gressin R; Casasnovas O; Marolleau JP; Tamburini J; Serrier C; Perez E; Paillassa J; Gyan E; Chauchet A; Ursu R; Kas A; Soussain C; Houillier C
Ann Hematol; 2023 May; 102(5):1159-1169. PubMed ID: 36991231
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series.
Provencher S; Ferlay C; Alaoui-Slimani K; Devidas A; Lepretre S; de Prijck B; Sebban C; de la Fouchardiere A; Chassagne-Clement C; Ketterer N; Thyss A; Delannoy A; Tilly H; Biron P; Blay JY; Ghesquières H
Hematol Oncol; 2011 Mar; 29(1):10-6. PubMed ID: 21381074
[TBL] [Abstract][Full Text] [Related]
3. Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.
Patel MP; Kirkpatrick JP; Johnson MO; Healy P; Herndon JE; Lipp ES; Miller ES; Desjardins A; Randazzo D; Friedman HS; Ashley DM; Peters KB
J Neurooncol; 2020 Apr; 147(2):477-483. PubMed ID: 32140975
[TBL] [Abstract][Full Text] [Related]
4. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.
Langner-Lemercier S; Houillier C; Soussain C; Ghesquières H; Chinot O; Taillandier L; Soubeyran P; Lamy T; Morschhauser F; Benouaich-Amiel A; Ahle G; Moles-Moreau MP; Moluçon-Chabrot C; Bourquard P; Damaj G; Jardin F; Larrieu D; Gyan E; Gressin R; Jaccard A; Choquet S; Brion A; Casasnovas O; Colin P; Reman O; Tempescul A; Marolleau JP; Fabbro M; Naudet F; Hoang-Xuan K; Houot R
Neuro Oncol; 2016 Sep; 18(9):1297-303. PubMed ID: 26951382
[TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
6. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study.
Houillier C; Soussain C; Ghesquières H; Soubeyran P; Chinot O; Taillandier L; Lamy T; Choquet S; Ahle G; Damaj G; Agapé P; Moluçon-Chabrot C; Amiel A; Delwail V; Fabbro M; Jardin F; Chauchet A; Moles-Moreau MP; Morschhauser F; Casasnovas O; Gressin R; Fornecker LM; Abraham J; Marolleau JP; Tempescul A; Campello C; Colin P; Tamburini J; Laribi K; Serrier C; Haioun C; Chebrek S; Schmitt A; Blonski M; Houot R; Boyle E; Bay JO; Oberic L; Tabouret E; Waultier A; Martin-Duverneuil N; Touitou V; Cassoux N; Kas A; Mokhtari K; Charlotte F; Alentorn A; Feuvret L; Le Garff-Tavernier M; Costopoulos M; Mathon B; Peyre M; Delgadillo D; Douzane H; Genet D; Aidaoui B; Hoang-Xuan K; Gyan E
Neurology; 2020 Mar; 94(10):e1027-e1039. PubMed ID: 31907289
[TBL] [Abstract][Full Text] [Related]
7. (R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study.
Collignon A; Houillier C; Ahle G; Chinot O; Choquet S; Schmitt A; Agape P; Soussain C; Hoang-Xuan K; Tabouret E
Ann Hematol; 2019 Apr; 98(4):915-922. PubMed ID: 30535802
[TBL] [Abstract][Full Text] [Related]
8. A single-center retrospective analysis of outcome measures and consolidation strategies for relapsed and refractory primary CNS lymphoma.
Bonm AV; Gibson AW; Holmberg LA; Mielcarek M; McGranahan T; Taylor LP; Graber JJ
J Neurooncol; 2021 Jan; 151(2):193-200. PubMed ID: 33398532
[TBL] [Abstract][Full Text] [Related]
9. Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study.
Younan N; Soussain C; Choquet S; Cassoux N; Touitou V; Schmitt A; Chinot O; Oberic L; Damaj G; Houot R; Ghesquières H; Laribi K; Ahle G; Taillandier L; Paillassa J; Gyan E; Jardin F; Delwail V; Marolleau JP; Tempescul A; Agapé P; Bourniquel M; Vacheret F; Jdid I; Le Garff-Tavernier M; Malaise D; Alentorn A; Xuan KH; Houillier C
Hematol Oncol; 2022 Dec; 40(5):976-986. PubMed ID: 35789106
[TBL] [Abstract][Full Text] [Related]
10. Lymphomas of Central Nervous System.
Yokogami K; Azuma M; Takeshima H; Hirai T
Adv Exp Med Biol; 2023; 1405():527-543. PubMed ID: 37452952
[TBL] [Abstract][Full Text] [Related]
11. Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
Fossard G; Ferlay C; Nicolas-Virelizier E; Rey P; Ducray F; Jouanneau E; Faurie P; Belhabri A; Sunyack MP; Chassagne-Clément C; Thiesse P; Sebban C; Biron P; Blay JY; Ghesquières H
Eur J Cancer; 2017 Feb; 72():12-19. PubMed ID: 28012348
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
13. Treatment of primary CNS lymphoma (PCNSL) following successful treatment of systemic non-Hodgkin's lymphoma (NHL): a case series.
Chamberlain MC
J Neurooncol; 2013 May; 113(1):27-32. PubMed ID: 23456654
[TBL] [Abstract][Full Text] [Related]
14. Primary central nervous system lymphomas: incidence and survival in the Southern and Eastern Netherlands.
van der Sanden GA; Schouten LJ; van Dijck JA; van Andel JP; van der Maazen RW; Coebergh JW;
Cancer; 2002 Mar; 94(5):1548-56. PubMed ID: 11920513
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network.
Soussain C; Choquet S; Blonski M; Leclercq D; Houillier C; Rezai K; Bijou F; Houot R; Boyle E; Gressin R; Nicolas-Virelizier E; Barrie M; Moluçon-Chabrot C; Lelez ML; Clavert A; Coisy S; Leruez S; Touitou V; Cassoux N; Daniau M; Ertault de la Bretonnière M; El Yamani A; Ghesquières H; Hoang-Xuan K
Eur J Cancer; 2019 Aug; 117():121-130. PubMed ID: 31279304
[TBL] [Abstract][Full Text] [Related]
16. Late relapse in primary central nervous system lymphoma: clonal persistence.
Nayak L; Hedvat C; Rosenblum MK; Abrey LE; DeAngelis LM
Neuro Oncol; 2011 May; 13(5):525-9. PubMed ID: 21372070
[TBL] [Abstract][Full Text] [Related]
17. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
Cheng T; Forsyth P; Chaudhry A; Morris D; Glück S; Russell JA; Stewart DA
Bone Marrow Transplant; 2003 Apr; 31(8):679-85. PubMed ID: 12692608
[TBL] [Abstract][Full Text] [Related]
18. Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
del Rio MS; Choquet S; Hoang-Xuan K; Glaisner S; Fourme E; Janvier M; Soussain C
J Neurooncol; 2011 Nov; 105(2):409-14. PubMed ID: 21656329
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
Du P; Chen H; Shen L; Liu X; Wu X; Chen L; Cao A; Geng D
Curr Oncol; 2022 Sep; 29(9):6642-6656. PubMed ID: 36135091
[TBL] [Abstract][Full Text] [Related]
20. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study.
Kasenda B; Schorb E; Fritsch K; Finke J; Illerhaus G
Ann Oncol; 2012 Oct; 23(10):2670-2675. PubMed ID: 22473593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
